Krabbe S, Eshed I, Sorensen IJ, et al. - This study was attempted to assess criteria for treatment response and remission in patients with axial axial spondyloarthritis (SpA) as evaluated by whole-body magnetic resonance imaging (WB-MRI) of axial and peripheral joints and entheses during treatment with golimumab. Researchers carried out an investigator-initiated cohort study including a total of 53 patients who had undergone WB-MRI at weeks 0, 4, 16 and 52 after initiation of golimumab. They evaluated images according to the Spondyloarthritis Research Consortium of Canada MRI SI joint inflammation index, Canada–Denmark MRI spine inflammation score and the MRI peripheral joints and entheses inflammation index. During golimumab treatment, WB-MRI indicated a significant reduction of inflammation in both the spine, sacroiliac joints and peripheral joints and entheses. Total WB-MRI remission was achieved by few patients. It was noted that combining spinal and sacroiliac joint inflammation in an MRI Axial Inflammation Index elevated the ability to capture response.